10. Brian Slingerland, Scott Dylla, and Daniel Reiner

Cofounders, Stemcentrx

Previously a Goldman Sachs vice president and a senior scientist at OncoMed Pharmaceuticals, respectively, Slingerland and Dylla publicly launched Stemcentrx in September along with Reiner, a serial investor and former telecom executive. Their mission: to end cancer by targeting cancer-specific stem cells.

Less than a year later, the pharma giant AbbVie bought the biotech startup for $10.2 billion, when the company was valued at $5 billion, in one of the largest tech acquisitions ever. AbbVie showed special interest in Stemcentrx's lung-cancer-fighting drug Rova-T, which could grow the company's oncology business. AbbVie hopes to bring the drug to market by 2018.